Skip to main
MDXG

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group is a strong player in the biologics industry, with a portfolio of successful amniograft products for the wound care and burn markets, as well as recent expansion into the surgical space. The company is well positioned to capitalize on the shift in settings of care and strong clinical data supporting its products. While recent reimbursement issues may have impacted the stock, its established track record and cost reduction initiatives make it a strong investment opportunity for long-term growth.

Bears say

MiMedx Group is struggling with sluggish recovery in the wound care market and the company is expected to incur a one-time restructuring charge in the second quarter of 2026. Additionally, there are risks related to tissue donorship and 361 regulated products, which could potentially impact the company's business. Furthermore, MDXG relies heavily on contracts with GPOs and IDNs, which could also pose a risk if terminated or not extended. While MDXG has a diverse portfolio of products and a strong track record, these risks and market challenges may hinder their future growth and financial performance.

MiMedx Group (MDXG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 5 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.